Sol-Gel Technologies: Phase 3 Gorlin Results Could Be The Next Major Catalyst

Sol-Gel Technologies is advancing toward late-November 2026 Phase 3 results for SGT-610 in Gorlin syndrome. The trial has a 9% dropout rate, with the last patient visit expected in September.